Viewing nowCombinationOlduo Tablet 5/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Samchundang Pharmaceutical Co., Ltd.

MFDS item code 201603903 · Approved 2016.06.24 · Insurance code 651205670
Treatment of essential hypertension not controlled by monotherapy
This medication is used to effectively lower blood pressure in patients with essential hypertension who have difficulty controlling their blood pressure with either amlodipine or olmesartan medoxomil alone. By managing blood pressure appropriately, it reduces the risk of cardiovascular complications and improves overall health.
Administer 1 tablet once daily with water, with or without food. It is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. Before administering this medicine, it is recommended that the dose of the individual components (amlodipine or olmesartan medoxomil) be adjusted. However, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy with the individual components. The maximum dose of this medicine is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min), the maximum dose of olmesartan medoxomil is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be monitored closely. This medicine should not be administered to patients with severe hepatic impairment (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine). ○ Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. In elderly patients, blood pressure should be monitored closely and more frequently.
○ Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This drug can cause severe harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Patients who are hypersensitive to any component of this drug, pregnant women, breastfeeding women, patients with severe liver impairment, patients with severe aortic stenosis, patients with bile duct obstruction, patients undergoing kidney dialysis, patients in shock, diabetic patients taking aliskiren, and patients with moderate to severe renal impairment should not take this medication. Patients with hypotension and dehydration may experience hypotensive symptoms during the initial period of taking this drug, requiring close monitoring of their condition, and appropriate measures if hypotension occurs. Since this drug acts as a vasodilator, it should be used cautiously in patients with severe aortic stenosis, severe obstructive coronary artery disease, congestive heart failure, renal impairment, and liver impairment. While taking this drug, various side effects may occur, including dizziness, headache, hypotension, orthostatic hypotension, drowsiness, edema, dyspepsia, skin rash, and so on, so if any abnormal symptoms arise, consult a physician or pharmacist. Women who are pregnant or planning to become pregnant should consult a healthcare provider before using this drug, and if pregnancy is confirmed, they should discontinue use as soon as possible. Breastfeeding women should be advised to stop breastfeeding or discontinue the drug while taking this medication, as it may be secreted into breast milk and could cause adverse reactions in infants. The safety and efficacy in children under 18 years of age have not been established, and this medication is not recommended for pediatric use. Elderly patients should start with a low dose and use it carefully due to the potential for decreased renal and liver function, and their condition should be monitored frequently. There may be interactions with other medications, so patients should inform their healthcare provider of any medications they are currently taking, especially when using potassium supplements, diuretics, lithium, and non-steroidal anti-inflammatory pain relievers. In cases of overdose, symptoms such as hypotension, tachycardia, etc., may occur, necessitating immediate medical treatment and monitoring. Store this medication away from direct sunlight and moisture, in a place inaccessible to children.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture, at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer period.
Pale yellow, round, film-coated tablet
28 tablets/PPTP [14 tablets/PTP x 2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Samchundang Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.